Article

Isolation, Absolute Configuration and Cytotoxic Activities of Alkaloids from *Hippeastrum goianum* (Ravenna) Meerow (Amaryllidaceae)

Mariacaterina Lianza,[#,a,b] Maria Helena Verdan,[#,b] Jean Paulo de Andrade,[b,c]
Ferruccio Poli,[a] Larissa C. de Almeida,[d] Leticia V. Costa-Lotufo,[d] Álvaro Cunha Neto,[b]
Sarah C. C. Oliveira,[e] Jaume Bastida,[f] Andrea N. L. Batista,[g]
João M. Batista Jr. [h] and Warley S. Borges [*,b]

[a]Department of Pharmacy and Biotechnology, Almer Mater Studiorum,
University of Bologna, CP 40126, Bologna, Italy

[b]Departamento de Química, Universidade Federal do Espírito Santo, 29075-910 Vitória-ES, Brazil

[c]Laboratorio de Química de Productos Naturales,
Instituto de Química de Recursos Naturales, y Núcleo Científico Multidisciplinario,
Dirección de Investigación, Universidad de Talca, CP 3460000, Talca, Chile

[d]Departamento de Farmacologia, Universidade de São Paulo, 05508-900 São Paulo-SP, Brazil

[e]Departamento de Botânica, Universidade de Brasília, 70910-900 Brasília-DF, Brazil

[f]Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l´Alimentació,
Universitat de Barcelona, CP 08028, Barcelona, Spain

[g]Instituto de Química, Universidade Federal Fluminense, 24020-141 Niterói-RJ, Brazil

[h]Instituto de Ciência e Tecnologia, Universidade Federal de São Paulo,
12231-280 São José dos Campos-SP, Brazil

The phytochemical study of *Hippeastrum goianum* led to the identification of 13 compounds by means of gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance (NMR). Compounds 7-demethoxy-9-*O*-methylhostasine (**1**) and 7-deoxy-*trans*-dihydronarciclasine (**2**) had their absolute configurations determined by vibrational circular dichroism (VCD). This is the first time that compound **1** is described in the Amaryllidaceae family. The cytotoxicity of all isolated compounds was tested against colorectal carcinoma (HCT 116), breast carcinoma (MCF-7), and non-tumor human retinal pigment epithelium (RPE) cell lines. The half-maximum inhibitory concentration (IC_{50}) of compound **2** against each cell line was equivalent to the positive control (doxorubicin), indicating a considerable cytotoxic activity.

Keywords: narciclasine, galasine, cytotoxic activity, absolute configuration, vibrational circular dichroism

Introduction

The genus *Hippeastrum*, belonging to the Amaryllidaceae family, Hippeastreae tribe, subfamily Amaryllidoideae, has about 70 species, distributed throughout Latin America, particularly in Brazil. The latest research pointed to the occurrence of about 30 Brazilian species, including 21 that are considered endemic.[1] Several studies[2] showed a peculiar taxonomy of the genus *Hippeastrum*, reinforcing the significance of chemical and pharmacological studies with these plants. Bulbs from many species of the genus *Hippeastrum* yielded numerous alkaloids, with 64 being fully characterized.[2] Considering the promising biological activities showed by these alkaloids, such as cytotoxic,[3] psychopharmacological[4] and acetylcholinesterase (AChE) inhibitory activities,[5] this class of compounds is of remarkable importance.

*e-mail: warley.borges@ufes.br

#These authors contributed equally to this study.

Isoquinolinic alkaloids from Amaryllidaceae plants, especially the narciclasine-type derivatives, have pronounced cytotoxic activities[6] and might be helpful in the cancer therapy. Cancer is a serious disease, considered the main cause of death in the world and many products used in the cancer therapy are natural products or natural products derivatives.[7-9] Therefore, it is important to search for new compounds that can be used against cancer.

This study was focused on *Hippeastrum goianum* (Ravenna) Meerow, an endemic species of Brazil, growing in the central-west part of the country, precisely in the Cerrado ecosystem.[10] Considering that little information on the phytochemical composition of *H. goianum* is available,[11] gas chromatography-mass spectrometry (GC-MS) based on qualitative and relative quantitative analysis was performed on hexane (*n*-Hex) and ethyl acetate (EtOAc) alkaloid-enriched extracts of the bulbs from this species. Out of the thirteen compounds identified by GC-MS, five were isolated and evaluated for cytotoxic activity against colon adenocarcinoma (HCT-116), breast carcinoma (MCF-7), and non-tumor retinal pigment epithelium (RPE) cell lines. Compounds 7-demethoxy-9-*O*-methylhostasine (**1**) and 7-deoxy-*trans*-dihydronarciclasine (**2**) had their absolute configurations determined by using vibrational circular dichroism (VCD) and compound **1** is reported for the first time in Amaryllidaceae family.

Experimental

General experimental procedures

The column chromatographic separations (CC) were done using silica gel (70-90 μm, Agela Technologies, Phenomenex Company, China) or Sephadex® (LH-20, GE Healthcare, USA). All Sephadex® columns were performed using methanol pro analysis (P.A.) (MeOH, LabSynth, Brazil) as mobile phase. For the acid-base extraction, the solvents sulfuric acid, ammonium hydroxide, *n*-hexane, ethyl acetate (EtOAc), and dichloromethane (DCM) of analytical grade were used (LabSynth, Diadema, Brazil). Preparative thin layer chromatography (PTLC) was performed with pre-coated aluminum plates with silica gel F_{254} (Macherey-Nagel®, France). The plates were analyzed by exposure under ultraviolet (UV) light (254 and 366 nm) and spraying with Dragendorff reagent. High-performance liquid chromatography (HPLC) purifications were done on an Agilent Chromatograph, coupled with a diode array (DAD) detector (1260 MWD), using a semi-preparative column (Eclipse XDB-18, 5 μm of particle size, 9.4 × 250 mm). All employed solvents were analytical grade, or HPLC grade when needed (LabSynth, Diadema,

Brazil). Gas chromatography analyses were performed on a GC-17A Shimadzu GC-MS QP 5000 operating in the electronic impact (EI) mode at 70 eV using a DB5 MS column (30 m × 0.25 mm × 0.25 μm). The temperature program was as follows: 100-180 ºC at 15 ºC min⁻¹, 1 min hold at 180 ºC and 180-300 ºC at 5 ºC min⁻¹ and 10 min hold at 300 ºC. The injector temperature was 280 ºC. The flow rate of carrier gas (helium) was 0.8 mL min⁻¹, and the split ratio was 1:20. The Amaryllidaceae alkaloids identified by GC-MS had their mass spectra deconvoluted using AMDIS 2.64 software (NIST)[12] and retention indices (RIs) recorded using a standard *n*-hydrocarbon calibration mixture (C9-C36). Thus, their GC-MS spectra and Kovats RI were compared to those presented in our library database. This library has been regularly updated with alkaloids isolated and unequivocally identified via physical and spectroscopic methods.

The ¹H, ¹³C and two-dimensional (2D) nuclear magnetic resonance (NMR) spectra were performed in a VNMRS400 spectrometer, operating at 9.4 T, using a 5 μm ¹H/X/D BroadBand probe. Deuterated chloroform (CDCl₃), methanol (CD₃OD) and dimethyl sulfoxide (DMSO-d_6) were used as solvent (Sigma-Aldrich, Steinheim, Germany). The nuclear Overhauser enhancement difference (NOEdiff) experiments were performed applying the one-dimensional nuclear Overhauser effect spectroscopy (1D-NOESY) pulse sequence, with the mixing time optimization for each experiment. HRESIMS (high-resolution electrospray ionization mass spectrometry) was performed on 9.4 T FT-ICRMS (Solarix, Germany) by direct injection of the compound dissolved in MeOH. Infrared (IR) and VCD spectra of **1** and **2**, were recorded with a Single-PEM Chiral IR-2X FT-VCD spectrometer (BioTools, Inc, Jupiter, FL, USA) using a resolution of 4 cm⁻¹ and a collection time of 7 h. The optimum retardation of the ZnSe photoelastic modulator (PEM) was set at 1400 cm⁻¹. Minor instrumental baseline offsets were eliminated from the final VCD spectrum by subtracting the VCD spectrum of each compound from that obtained for the solvent under identical conditions. The IR and VCD spectra were recorded in a BaF₂ cell with 100 μm path length using DMSO-d_6 as solvent. The samples were prepared as follows: 6 mg of compound **1** and 3 mg of compound **2**, both dissolved in 120 μL of DMSO-d_6.

Plant material

Bulbs from *Hippeastrum goianum* (Ravenna) Meerow were harvested at the University of Brasília, Brasília, Distrito Federal, Brazil in September 2016. The material was identified by Dr Sarah Christina Caldas Oliveira and

a voucher was deposited at the Herbarium of the Federal University of Espírito Santo (VIES 39499). Registration SisGen No. A012E5E.

Extraction and isolation

Bulbs (2.1 kg) were dried at 40 ºC and crushed. The resulting material (579 g) was extracted with MeOH (4 times, 24 h each). The dried extract (148 g) was acidified with sulfuric acid (2%) to pH 2 and further extracted with petroleum ether (PE) (3 × 200 mL) and ethyl acetate (EtOAc) (3 × 200 mL). The aqueous solution was basified with ammonium hydroxide (30%) to pH 9-10 and then extracted with *n*-hexane (7 × 150 mL) to give extract C (57.3 mg), EtOAc (20 × 150 mL) to produce extract D (8.2 g), from which compound **2** precipitated (530.6 mg), and EtOAc-MeOH (3:1) (3 × 150 mL) that gave extract E (9.2 g), all of which showed positive results for alkaloids according to Dragendorff's reagent. Extracts C and D were analyzed by GC-MS. Extract D was fractionated by Sephadex® column eluted with MeOH, resulting in 69 fractions, grouped in three main fractions. Fraction D.2 (6.6 g) was subjected to Sephadex® column giving 50 fractions, combined in four subfractions based on TLC profiles. Subfraction D.2.2 (732.3 mg) was submitted to a new Sephadex® column resulting in 81 fractions, grouped in five subfractions. Subfraction D.2.2.2 (517.9 mg) was fractionated by silica gel CC eluted on EtOAc containing increasing amounts of a solution with DCM and MeOH (1:1) until the proportion of the mixture DCM-MeOH reached 100%. This resulted in 111 fractions that were grouped in five subfractions after TLC analysis. Subfraction D.2.2.2.2 (60.6 mg) was identified as compound **1**. Fraction D.2.3 (5.7 g) was submitted to silica gel CC first eluted with EtOAc, then gradients of DCM-MeOH (1:1, 0 → 100%) were added, yielding 262 fractions and combined in 11 subfractions. Subfractions D.2.3.4, D.2.3.7, D.2.3.8 and D.2.3.10 showed positive results for alkaloids (positive Dragendorff's spots). Subfraction D.2.3.4 (578.8 mg) was subjected to silica gel CC eluted with EtOAc followed by gradients of DCM-MeOH (1:1, 0 → 100%) providing 112 fractions, which were combined in four subfractions. Compound **1** was obtained from subfraction D.2.3.4.2 (321.0 mg) after PTLC in *n*-hexane-DCM-EtOAc-acetone-MeOH (3:1.5:2:1.5-5 drops of ammonium hydroxide were add into the solvent system) as elution system. Subfraction D.2.3.7 (254.8 mg) was submitted to Sephadex® column, resulting in 60 fractions grouped in nine subfractions. Subfraction D.2.3.7.5 (41.1 mg) was subjected to PTLC in EtOAc-CHCl$_3$-acetone-MeOH (5:5:3:5), resulting in the precipitation of compound **11** (9.4 mg). Subfraction

D.2.3.8 (588.2 mg) was submitted to Sephadex® column, resulting in 62 fractions grouped in five subfractions. Compound **13** (4.3 mg) precipitated from subfraction D.2.3.8.2 (206.7 mg). Subfraction D.2.3.10 (267.4 mg) was subjected to Sephadex® column resulting in 60 fractions combined in four subfractions. Subfraction D.2.3.10.1 (175.9 mg) was fractionated with CC of silica gel eluted with DCM, gradients of MeOH on DCM and pure MeOH, yielding 74 fractions, grouped in four subfractions. Subfraction D.2.3.10.1.2 (16.3 mg) was submitted to HPLC fractionation employing a gradient method with H$_2$O and MeOH. The method (7 mL min^{-1}) increased the amount of MeOH from 10 to 50% in 20 min, then returned to 10% in 5 min, and this percentage was kept for 10 min. The first band that eluted at 3.14 min was extracted with CHCl$_3$-MeOH (4:1) and identified as compound **6** (2.0 mg).

Cell culture and MTT assay

HCT-116 (colon adenorcarcinoma) cells were grown in Roswell Park Memorial Institute medium (RPMI) and MCF-7 (breast carcinoma) and RPE (non-tumor retinal pigment epithelium) cells were grown in Dulbecco's modified Eagle medium (DMEM). Both media were supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics (penicillin 10,000 Units mL^{-1} and streptomycin 10,000 μg mL^{-1}). Cells were kept in an incubator with 5% CO$_2$ at 37 °C. For 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, the cells were seeded on 96-well plates at a density of 1×10^4 *per* well with 200 μL culture medium. After 24 h, compounds **1**, **2**, **6**, **11** and **13** (0.0032-50 μM) were added to the cultures and incubated for 72 h. DMSO (0.05%) was used as negative control and the antineoplastic compound doxorubicin (0.00064-10 μM) was used as positive control. Three hours before the end of the experiment, culture media were replaced by fresh media containing MTT solution (0.5 mg mL^{-1}) and incubated. The MTT solution was removed and the formazan product was solubilized in 150 μL DMSO. The absorbance was obtained at 540 nm. The IC$_{50}$ values and their 95% confidence interval were calculated by sigmoidal nonlinear regression using GraphPad Prism 8.0 software.[13]

Calculations

Conformational searches were carried out at the molecular mechanics level of theory with the Monte Carlo algorithm employing the MM+ force field incorporated in HyperChem 8.0.10 software package.[14] Calculations were performed for the arbitrarily chosen (1*R*,2*S*,4a*R*,10b*R*)-**1**

and (2S,3R,4S,4aR,10bR)-**2**. Initially, 68 conformers of (1R,2S,4aR,10bR)-**1** with relative energy (rel E.) within 10 kcal mol^{-1} of the lowest-energy conformer were selected and further geometry optimized at the B3LYP/PCM(DMSO)/6-31G(d) level. The five conformers with rel E. < 1.0 kcal mol^{-1} were selected for IR and VCD spectral calculations. The inclusion of explicit DMSO molecules was performed using Hyperchem software,[14] on the optimized conformers of compound **1** obtained at the B3LYP/PCM(DMSO)/6-31G(d) level, which were subsequently subjected to geometry optimization and frequency calculations at the same level. As for (2S,3R,4S,4aR,10bR)-**2**, 12 conformers with relative energy (rel E.) within 10 kcal mol^{-1} of the lowest-energy conformer were selected and further geometry optimized at the B3LYP/PCM(DMSO)/6-31G(d) level. The four conformers with rel E. < 1.2 kcal mol^{-1} were selected for IR and VCD spectral calculations. All density functional theory (DFT) calculations were carried out at 298 K in DMSO solution using the polarizable continuum model (PCM) in its integral equation formalism version (IEFPCM) incorporated in Gaussian 09 software.[15] For the IR and VCD spectral simulations, the spectra were created using dipole and rotational strengths from Gaussian, which were calculated

at the same level used during the geometry optimization step, and converted into molar absorptivities (M^{-1} cm^{-1}). Each spectrum was plotted as a sum of Lorentzian bands with half-widths at half-maximum of 6 cm^{-1}. The calculated wavenumbers were multiplied with a scaling factor of 0.975. The final spectra were generated according to Boltzmann weighting of the lowest-energy conformers identified and plotted using Origin 8 software.[16]

7-Demethoxy-9-*O*-methylhostasine (**1**)

Amorphous yellowish solid. ^{1}H and ^{13}C NMR data see Table 1 and Figures S1-S10 (Supplementary Information (SI) section). HRESIMS *m/z*, calcd. for $C_{18}H_{22}NO_6^+$ [M + H]$^+$: 348.14417, found: 348.14458; calcd. for $C_{36}H_{43}N_2O_{12}^+$ [2M + H]$^+$: 695.28105, found: 695.28416; calcd. for $C_{54}H_{63}N_3NaO_{18}^+$ [3M + Na]$^+$: 1064.39989, found: 1064.40808; calcd. for $C_{72}H_{84}N_4NaO_{24}^+$ [4M + Na]$^+$: 1411.53677, found: 1411.55830 (Figure S11, SI section).

7-Deoxi-*trans*-dihydronarciclasine (**2**)

Amorphous white solid. ^{1}H and ^{13}C NMR data see Table 2 and Figures S13-S19 (SI section). HRESIMS *m/z*, calcd. for $C_{14}H_{16}NO_6^+$ [M + H]$^+$: 294.09722, found: 294.09717; calcd. for $C_{28}H_{31}N_2O_{12}^+$ [2M + H]$^+$: 587.18715,

Table 1. NMR data for compound **1** in 400 MHz and comparison with the literature (400 MHz, MeOD)[17]

Position	δ_H, mult. (*J* / Hz)^a	$\delta_C^{a,b}$	COSY^a	HMBC^a	δ_H, mult. (*J* / Hz)^c	δ_C^c	HMBC^c	δ_H, mult. (*J* / Hz)^{17}	δ_C^{17}
1	3.82 brs	76.3	N.O.	10b	3.60 brt (1.2)	78.1	N.O.	3.60 s	78.1
2	4.13 brs	70.9	3	N.O.	4.09-4.13 m	72.4	N.O.	4.10 s	72.4
3	5.70 brs	118.2	2, 4a, 11	N.O.	5.67-5.71 m	120.2	N.O.	5.70 brs	120.3
4	–	141.7	–	–	–	141.7	–	–	141.6
4a	3.40 brs	65.5	3, 11	N.O.	3.47-3.50 m	67.1	4, NMe	3.49 s	67.1
6	–	N.O.	–	–	–	171.5	–	–	171.4
6a	–	117.4	–	–	–	118.7	–	–	118.8
7	7.28 s	106.0	N.O.	9, 10a	7.36 s	107.5	6, 9, 10a	7.34 s	107.0
8	–	150.9	–	–	–	152.7	–	–	152.7
9	–	154.4	–	–	–	156.3	–	–	156.3
10	7.23 s	105.5	N.O.	6a, 8, 9	7.35 s	107.1	6a, 8	7.35 s	107.5
10a	–	145.6	–	–	–	147.2	–	–	147.1
10b	–	83.7	–	–	–	85.1	–	–	85.0
11α/β	2.47-2.55 m	27.7	3, 12α, 12β	4	2.41-2.62 m	28.8	N.O.	2.58 m-2.48 m	28.7
12α	3.10 ddd (9.6, 6.0, 4.0)	55.2	11, 12β	N.O.	3.04 ddd (9.6, 8.0, 2.4)	56.7	4	3.05 m	56.8
12β	2.27 q (9.6)		11, 12α	N.O.	2.33 q (9.6)		NMe	2.36 dd (18.4, 9.2)	
8-OCH$_3$	3.92 s	56.1	–	8	3.92 s	56.7	8	3.92 s	56.7
9-OCH$_3$	3.97 s	56.3	–	9	3.97 s	56.9	9	3.96 s	56.9
N-CH$_3$	1.61 s	43.2	–	4a, 12	1.65 s	43.4	4a, 12	1.66 s	43.4

^{a}CDCl$_3$; ^{b}shifts were obtained using the correlations observed in the HSQC and HMBC spectra; ^{c}MeOD. δ_H: chemical shift of hydrogen; mult.: multiplicity of hydrogen; *J*: coupling constants; δ_C: chemical shift of carbon-13; HMBC: heteronuclear multiple bond correlation; N.O.: not observed.

Table 2. NMR data for compound **2** (400 MHz, DMSO-d_6) and comparison with literature[18,19]

Position	δ_H, mult. (J / Hz)	δ_C	COSY	HMBC	δ_H, mult. (J / Hz)[19] (300 MHz, DMSO-d_6)	δ_H[18] (500 MHz, DMSO-d_6)	δ_C[18] (125 MHz, DMSO-d_6)
1α	2.14 dt (13.2, 3.4)	28.4	1β, 2, 3, 10, 10b	2, 3	1.59 dt (13.4, 2.3)	2.14 dt	28.2
1β	1.64 td (13.2, 2.4)		1α, 2, 10b	10b	2.12 brd (13.3)	1.65 td	
2	3.89 s	68.7	1α, 1β, 3, 2-OH	4, 10b	3.84 s	3.70 s	69.6
3	3.72 brs	71.7	1α, 2, 3-OH, 4	1, 4a	3.68 brs	3.87 s	68.5
4	3.72 brs	69.8	3, 4a, 4-OH	4a	3.68 brs	3.70 s	71.6
4a	3.31 dd (12.4, 9.6)	55.2	4, 10b	4	3.23 m	3.31 s	55.0
6	–	164.4	–	–	–	–	164.2
6a	–	123.3	–	–	–	–	123.2
7	7.30 s	107.0	10	6, 9, 10a	7.30 s	7.29 s	106.8
8	–	146.0	–	–	–	–	145.8
9	–	150.7	–	–	–	–	150.5
10	6.92 s	104.4	1α, 7, 10b	7, 8, 9, 10b	6.89 s	6.92 s	104.2
10a	–	138.1	–	–	–	–	137.9
10b	2.88 td (12.4, 3.6)	34.3	1α, 1β, 4a, 10	4a, 10a	2.84 dt (12.8, 3.4)	2.90 td	34.2
2-OH	5.02 s	–	2	–	4.91 s	4.96 s	–
3-OH	4.84 s	–	3	–	4.74 s	4.92 s	–
4-OH	4.96 s	–	4	–	4.91 s	4.80 s	–
5-NH	6.93 s	–	–	4, 4a, 6, 6a	6.89 s	6.92 s	–
OCH$_2$O	6.06 s	101.7	–	8, 9	6.03 s	6.06 s	101.5

δ_H: chemical shift of hydrogen; mult.: multiplicity of hydrogen; J: coupling constants; δ_C: chemical shift of carbon-13; COSY: homonuclear correlation spectroscopy; HMBC: heteronuclear multiple bond correlation.

found: 587.18702; calcd. for $C_{28}H_{30}N_2NaO_{12}{}^+$ [2M + Na]$^+$: 609.16910, found: 609.16907 (Figure S20, SI section).

Results and Discussion

GC-MS analyses

The alkaloids identified from the bulbs of *H. goianum* through GC-MS analysis are shown in Table 3 and Figure 1. It is not common to observe a high content of primary metabolites in an alkaloid-enriched extract obtained by acid-base extraction, however, the *n*-hexane extract was composed of approximately 70% of hexadecanoic, octadecenoic and octadecadienoic acid derivatives. It is well-documented that the GC-MS method applied herein for Amaryllidoideae plant matrices detects primary metabolites in short retention time (data not shown).[20] Regarding the Amaryllidaceae alkaloids detected by GC-MS, galanthamine, crinane, lycorine and homolycorine-type series have been determined in bulbs of the species (Table 3). The hostasine derivative 7-demethoxy-9-*O*-methylhostasine (**1**) was the main

component in the EtOAc fraction (43.7%) followed by 9-*O*-demethyllycoramine (**6**-20.9%), lycorine (**11**-14.7%) and pseudolycorine (**13**-8.0%). The outstanding structural difference between a galasine-type and a homolycorine-type derivative is the presence of a five-member lactone in the former rather than a six-membered one in the latter,[21] even though the pyrrolidine moieties in both skeleton series are essentially the same. Actually, it has been noticed parallels between the electronic impact-mass fragmentation of **1** and that observed for the typical homolycorine-type skeleton.[22] The low abundance of the molecular ion and the base peak at *m/z* 125 in **1** were also detected in the electronic impact-mass fragmentation of the 2-hydroxy substituted homolycorine-type derivative hippeastrine.[23] The fragmentation route of homolycorine-type alkaloids under electronic impact (EI) ionization method is well established and is dominated by the retro-Diels-Alder reaction in the hexahydroindole ring, which leads to the cleavage of the labile bonds and generates a base peak fragment representative of the pyrrolidine ring moiety (*m/z* 109), along with any substituent at C-2.[21-23] Thus, as in 2-hydroxyhomolycorine-type derivatives, the *m/z* 125

in **1** is consistent with the pyrrolidine ring moiety along with the hydroxyl substituent at C-2. Further evaluations under EI ionization source of galasine-type compounds are needed to confirm their fragmentation mode in EI mass spectrometry. The galasine-type skeleton was found for the first time in *Galanthus* genus in 1995,[24] and only recently was characterized in the species *Hosta plantaginea*, a representative of the Asparagaceae family.

The alkaloids 8-*O*-demethylhomolycorine (**12**) and sanguinine (**4**) were also detected as minor components in addition to some undefined compounds, which were determined as homolycorine representatives due to the base peaks both at *m/z* 125 and 109. Regarding the *n*-hexane extract, similarly to what was mentioned above, the alkaloid relative content observed by GC-MS was remarkably smaller than the percentage of primary metabolites. In this fraction, the two main compounds detected by GC-MS were undefined alkaloids corresponding to 11.3 and 8.3% of the TIC. These two compounds along with the other undefined alkaloids (2.0%) have demonstrated electronic impact-mass fragmentation typical to Amaryllidaceae alkaloids, even though the use of fragmentation patterns based solely on EI-MS technique is not enough for any speculation about the skeleton-type. The small relative percentage of these undefined compounds and the low mass of extract in *n*-hexane (57.3 mg) were evident limitations for their purification and characterization. Lycorine derivatives, such as anhydrolycorine (**8**-2.5%) and dihydro-1-acetyllycorine (**10**-0.9%), along with the aulicine (**9**-2.1%) showed low relative percentage and galanthamine (**3**) along with vittatine/crinine (**7/7a**) were detected as traces (less than 0.5%).

NMR approaches

In the course of the fractionation procedure, the hostasine derivative 7-demethoxy-9-*O*-methylhostasine (**1**), the narciclasine derivative 7-deoxi-*trans*-dihydronarciclasine (**2**), 9-*O*-demethyllycoramine (**6**), lycorine (**11**) and pseudolycorine (**13**) were purified from the bulbs of *H. goianum*. Additionally, seven compounds were identified by means of GC-MS approaches. The chemical structures of the 13 identified compounds are shown in Figure 2.

Compound **1** was isolated as an amorphous yellowish solid with molecular formula determined by HRESIMS data, displaying a *m/z* 348.14458 peak consistent with the $[M + H]^+$ ion for the molecular formula $C_{18}H_{22}NO_6$, with theoretical *m/z* 348.14417. It is consistent with nine indices of hydrogen deficiency. The NMR data for compound **1** were very similar to those of 8-demethoxy-10-*O*-methylhostasine,[17] which is also named as 7-demethoxy-9-*O*-methylhostasine, according to the numbering proposed by Ghosal *et al*.[25] The downfield region of the ^{1}H NMR of compound **1** showed two *para* aryl hydrogens at δ_H 7.36 (s, H-7) and at δ_H 7.35 (s, H-10) along with an olefinic hydrogen at δ_H 5.67-5.71 (m, H-3) and two resonances at δ_H 3.60 (brt, 1.2 Hz, H-1) and at δ_H 4.09-4.13 (m, H-2), which were consistent with the oxymethinic hydrogens H-1 and H-2, respectively. The two aromatic methoxyl groups were suggested by the chemical shift at δ_H 3.92 (s) and at δ_H 3.97 (s) (3H both) and confirmed through HMBC experiment as 8-OMe and 9-OMe groups (Table 1), respectively. The *N*-methyl group was assigned as a singlet at δ_H 1.65, in agreement to its homologous in 8-demethoxy-10-*O*-methylhostasine.[17] Striking differences were observed in the splitting pattern of the methylene positions of the pyrrolidine ring, in comparison to the NMR data of 8-demethoxy-10-*O*-methylhostasine.[17] As observed in others homolycorine derivatives, the H-12α was split into a ddd with the geminal coupling constant $J_{12\alpha,12\beta} = 9.6$ Hz, which is in agreement with other homolycorine-and lycorine-type series, the latter of which is biogenetically related to homolycorines.[26,27] In this attempt,


Figure 1. GC-MS spectra of the fractions (a) *n*-hexane and (b) ethyl acetate, obtained from bulbs of *Hippeastrum goianum*.

Table 3. GC-MS data of bulbs of *H. goianum*. Values are expressed as a relative percentage of total ion current (TIC)

Alkaloid	RI	Bulb extract		M⁺	MS
		n-Hex / %	EtOAc / %		
Galanthamine (**3**)	2394	tr	–	287(83)	286(100), 270(13), 244(24), 230(12), 216(33), 174(27), 115(12)
Sanguinine (**4**)	2403	–	1.0	273(100)	272(79), 256(18), 216(18), 202(37), 160(44), 115(25)
Lycoramine (**5**)	2410	2.6	–	289(62)	288(100), 232(8), 202(14), 187(14), 159(9), 115(19)
9-*O*-Demethyllycoramine (**6**)	2463	–	20.9	275(55)	274(100), 174(10), 173(14), 145(10), 131(11), 115(14), 44(35)
Vitatine (**7**), crinine (**7a**)ᵃ	2470	tr	–	271(100)	228(25), 199(95), 187(85), 173(28), 128(32), 115(33), 56(22)
Anhydrolycorine (**8**)	2501	2.5	–	251(43)	250(100), 192(13), 191(11), 165(4), 164(3), 139(2), 124(7)
Aulicine (**9**)	2656	2.1	–	319(100)	304(19), 288(37), 246(18), 233(73), 218(19), 206(26), 163(7)
Dihydro-1-acetyllycorine (**10**)	2737	0.9	–	331(41)	330(100), 270(28), 254(30), 226(10), 147(12), 119(7), 89(5)
Lycorine (**11**)	2746	–	14.7	287(31)	286(19), 268(24), 250(15), 227(79), 226(100), 211(7), 147(15)
Undefined A	2810	8.3	–	349(27)	318(19), 276(27), 248(100), 167(9), 142(17), 96(25), 55(9)
8-*O*-Demethylhomolycorine (**12**)	2833	–	1.7	301(< 1)	195(0.5), 164(2), 109(100), 108(25), 94(3), 82(3)
Undefined B (homolycorine-type 2-hydroxy substituted derivative)	2887	–	2.4	nd	181(14), 138(19), 125(100), 124(9), 111(5), 96(57), 95(8)
Undefined C (homolycorine-type derivative)	2888	–	1.1	nd	194(5), 163(3), 109(100), 108(18), 92(3), 66(4), 58(4)
Pseudolycorine (**13**)	2823	–	8.0	289(28)	270(19), 252(15), 228(100), 214(9), 147(16), 111(18), 82(11)
Undefined D	2948	11.3	–	373(47)	372(100), 314(53), 272(45), 254(87), 212(14), 147(26), 119(11)
Undefined E	2985	2.0	–	331(40)	330(100), 270(71), 254(22), 212(18), 147(36), 91(23), 77(15)
7-Demethoxy-9-*O*-methylhostasine (**1**)	3057	–	43.7	nd	125(100), 124(8), 96(35), 81(3), 77(2), 67(2), 53(3)

ᵃThe known compounds **7** and **7a**[21] cannot be defined only by means of GC-MS. Compound **2** cannot be analyzed by GC-MS technique. RI: Kovats retention indices; M⁺: molecular ion; MS: MS fragments of the compounds by electron impact; nd: not detected; tr: traces.

the complete and correct assignment for compound **1** is suggested at Table 1 and confirmed it as 7-demethoxy-9-*O*-methylhostasine. This is the first time that a hostasine derivative is isolated from a species of Amaryllidaceae. Based on the relative configuration determined from NMR data, the absolute configuration of compound **1** was unambiguously assigned by comparison of experimental and calculated VCD spectra. The correlation between observed and theoretical data obtained at the B3LYP/PCM(DMSO)/6-31G(d) level (Figure S12, SI section) led to the assignment of compound **1** as 1*R*,2*S*,4a*R*,10b*R*. It is noteworthy that the best agreement with experimental data was observed after the inclusion of explicit DMSO solvation during the DFT simulation.[28]

This compound was previously isolated only from *Hosta plantaginea* a species from the family Asparagaceae.[17] This is the first report of 7-demethoxy-9-*O*-methylhostasine in the Amaryllidoideae subfamily.

Compound **2** had its molecular formula determined by the HRESIMS signal of *m/z* 294.09717, consistent with the [M + H]⁺ ion for the molecular formula $C_{14}H_{16}NO_6$, with theoretical *m/z* 294.09722. Its ¹H NMR spectrum showed signals due to aromatic hydrogens at δ_H 7.30 (s, H-7) and δ_H 6.92 (s, H-10), a NH hydrogen at δ_H 6.93 (s, NH-5), three hydroxyl groups at δ_H 5.02 (s, 2-OH); at δ_H 4.96 (s, 4-OH) and at δ_H 4.84 (s, 3-OH); and two hydrogens with a *trans* relationship at δ_H 2.88 (td, 12.4, 3.6 Hz, H-10b)

Figure 2. Chemical structures of the isolated and identified compounds in *Hippeastrum goianum*.

and at δ_H 3.31 (dd, 12.4, 9.6 Hz, H-4a), which indicates a 1,10b-dihydronarciclasine derivative. According to the ^{13}C NMR spectrum, there are fourteen carbons, being one of them assigned to an acyl group at δ_C 164.4, six aromatic carbons (δ_C 104.4, 107.0, 123.3, 138.1, 146.0, 150.7), one methylenedioxide carbon (δ_C 101.7), five methine carbons (δ_C 34.3, 55.2, 68.7, 69.8, 71.7) and one methylene carbon (δ_C 28.4). Analysis of the COSY spectrum showed that H-10b has correlation with H-1β resonant at δ_H 1.64, H-1α (δ_H 2.14), H-4a (δ_H 3.31), and H-10 resonant at δ_H 6.92, while H-2 at δ_H 3.89 displayed correlation with H-1β (δ_H 1.64), H-1α (δ_H 2.14), H-3 (δ_H 3.72) and 2-OH (δ_H 5.02). These data were consistent with the structure of 7-deoxi-*trans*-dihydronarciclasine (Figure 2, Table 3). COSY, NOE experiments and *J* values, allowed us to describe the relative stereochemistry of the stereogenic carbons. Irradiation of H-1β (δ_H 1.64) resulted in NOE with H-1α (δ_H 2.14), H-4a (δ_H 3.31), H-2 (δ_H 3.89), and H-10 (δ_H 6.92). When H-1α (δ_H 2.14) was irradiated, NOE was observed with H-1β (δ_H 1.64), H-10b (δ_H 2.88), H-2 (δ_H 3.89), and H-10 (δ_H 6.92). Additionally, H-10b (δ_H 2.88) was irradiated showing NOE with H-1α (δ_H 2.14), H-4 (δ_H 3.72), and H-10 (δ_H 6.92). The proposed relative stereochemistry is in accordance with the literature[18] where H-1β has spatial interaction with its geminal hydrogen H-1α, as well as H-4a and H-2. The

hydrogen H-2 is in gauche conformation between H-1α and H-1β and its spatial correlation would be observed for both irradiations on H-1. The relative configurations of H-2 and H-4 are corroborated by NOE experiments since only the irradiation on H-10b (δ_H 2.88) resulted in correlation with the oxymethinic hydrogen H-4. The 1D (one-dimension)-NOE correlation of the irradiated H-1β, H-1α, and H-10b is depicted in Figure 3.

The mono- and bi-dimensional NMR experiments (1D/2D NMR) were essential for the assignment of the relative configuration of **2**, even though the overlapped H-3 and H-4 resonances along with the absence of resolved NOE correlation in the case of H-3 did not assure the orientation of the 3-hydroxyl group. To confirm the absolute stereochemistry of **2**, VCD analyses were performed. The comparison of experimental and calculated IR and VCD data at the B3LYP/PCM(DMSO)/6-31G(d) led to the assignment of its absolute configuration as 2*S*,3*R*,4*S*,4a*R*,10b*R* (Figure S21, SI section). In this case, simulations of implicit solvation using the polarizable continuum model (PCM) were enough for an accurate reproduction of the experimental spectra. This compound was first isolated from species of *Hymenocallis* genus[19] and more recently from *Scadoxus pseudocaulus*, besides other species from the Amaryllidaceae family.[29]

Figure 3. 1D-NOE correlation for compound **2**.

Compound **6** was identified as 9-*O*-demethyllycoramine after comparison of its NMR data (Figures S22-S25, SI section) with the literature. This compound was previously obtained from *Lycoris radiata* (Amaryllidaceae)[30] and compounds **11** and **13** were identified as lycorine and pseudolycorine, respectively. These compounds are commonly found in Amaryllidaceae species.[21] Their NMR data can be seen in Table S1 (SI section).

Cytotoxic activity

Results of tumor growth inhibition obtained from MTT assay[31] showed the sensitivity of colorectal (HCT-116) and breast (MCF-7) carcinoma cell lines, as well as of non-tumor retinal pigment epithelium cell line, for 7-deoxi-*trans*-dihydronarciclasine (**2**) and pseudolicorine (**13**) (Table 4, Figure S28, SI section). The half-maximum inhibitory concentration (IC_{50}) of narciclasine derivative (**2**) for each

cell line is comparable to the positive control (doxorubicin), indicating its considerable cytotoxic activity. Compound **13** is less cytotoxic than compound **2**; however, it is ten times more selective to HCT-116 cell line in comparison to the non-tumor cell line RPE (Table 4). The high cytotoxicity of compound **2** from *Hippeastrum goianum* with IC_{50} varying from 0.15 to 0.2 μM is consistent with the cytotoxic potential of Amaryllidaceae isocarbostyrils in general, which generally show IC_{50} smaller than 1 μM against carcinomas, gliomas and menanomas cells.[32] Compound **2**, isolated from *Hymenocallis littoralis*, showed potent cytotoxicity in a panel of cancer cell lines from different origins, including MCF-7, where they found a IC_{50} (0.1 μM) similar to the one obtained herein.[33] Compound **2** is actually consistently less active than narciclasine, that presented IC_{50} values ranging from 0.01 to 0.09 μM against four different cell lines.[34] Pseudolycorine (**13**), isolated from another genus from the Amaryllidaceae family (*Narcissus tazetta*),

Table 4. Mean inhibitory concentration (IC_{50}) and confidence interval (95%) of the compounds **1**, **2**, **6**, **11**, **13** and the positive control doxorubicin in colorectal carcinoma (HCT 116), mammary carcinoma (MCF-7) and non-tumor human retinal pigment epithelium (RPE) cell lines (mean ± SEM) (n = 3)

Compound	HCT-116		MCF-7		RPE	
	IC_{50} / μM	Confidence intervals 95%	IC_{50} / μM	Confidence intervals 95%	IC_{50} / μM	Confidence intervals 95%
1	> 50	–	> 50	–	> 50	–
2	0.15	0.10-0.22	0.2	0.1-0.3	0.3	0.2-0.6
6	> 50	–	> 50	–	> 50	–
11	> 50	–	> 50	–	> 50	–
13	4.6	3.4-6.0	10.6	8.9-12.6	42.6	32.0-56.7
Doxorubicin	0.4	0.24-0.62	0.6	0.4-0.8	1.2	0.8-1.6

has previously shown promising cytotoxicity against two different cervical carcinoma cell lines.[35] When isolated from *H. solandriflorum*,[34] compound **13** showed higher cytotoxicity than observed herein, where the obtained IC_{50} values against the tumor cell line HCT-116 were 5.4 times higher when compared to the previous work (IC_{50} 0.85 μM).

Conclusions

In summary, thirteen Amaryllidaceae alkaloids were unambiguously identified from the indigenous Brazilian species *Hippeastrum goianum* by means of GC-MS, 1D/2D-NMR, and VCD methods. For the first time in Amaryllidoideae species (former Amaryllidaceae family) compound **1** has been characterized. Compound **1** is a representative of a very uncommon five-membered lactone moiety skeleton in Amaryllidoideae plants, which has been very recently accepted as a new subgroup named galasine-skeleton. The determination of another representative of the galasine-type skeleton in Amaryllidoideae subfamily is an outstanding finding in terms of chemotaxonomy. Furthermore, the complete and unambiguous NMR data for compound **1** along with the determination of its absolute configuration by means of VCD is reported herein. Compound **2** is a representative of the cytotoxic skeleton narciclasine-type, an isocarbostyril derivative. The complete and unambiguous assignment of **2** using 1D/2D NMR experiments led to the relative configuration of its stereocenters. The use of VCD spectroscopy allowed the determination of its absolute configuration, confirming the typical stereochemistry described in narciclasine-type skeletons from Amaryllidoideae plants. VCD has been successfully applied for stereochemical studies of a tazettine derivative,[36] but this is the first time VCD spectroscopy is used in narciclasine-type alkaloids. In terms of the cytotoxic activity of **2**, it has been previous studied against a wide range cancer cell lines, and the observed IC_{50} values are in the same range (0.1-0.2 μM) than the ones described herein, endorsing **2** as a promising anticancer compound. These findings emphasize the great chemical and biological potential of the Amaryllidoideae species.

Supplementary Information

Supplementary information (NMR, VCD and MS data) are available free of charge at http://jbcs.sbq.org.br as PDF file.

Acknowledgments

Author Contributions

M.L. was responsible for investigation; M.H.V. for investigation, writing original draft; J.P.A. for investigation, writing original draft; F.P. for conceptualization; L.C.A. for investigation; L.C.V.L. for conceptualization; A.C.N. for investigation; S.C.C.O. for investigation; J.B. for conceptualization, writing-review and editing; A.N.L.B. for investigation; J.M.B.J. for investigation; W.S.B. for conceptualization, project administration, resources, writing original draft.

References

1. Judd, W. S.; Campbell, C. S.; Kellogg, E. A.; Stevens, P. F.; Donoghue, D. J.; *Plant Systematics: A Phylogenetic Approach*, 3rd ed.; Sinauer Associates, Inc.: Sunderland, USA, 2008.

2. de Andrade, J. P.; Pigni, N. B.; Torras-Claveria, L.; Guo, Y.; Berkov, S.; Reyes-Chilpa, R.; Amrani, A. E.; Zuanazzi, J. A. S.; Codina, C.; Viladomat, F.; Bastida, J.; *Rev. Latinoam. Quim.* **2012**, *40*, 83.

3. Silva, A. F. S.; de Andrade, J. P.; Machado, K. R. B.; Rocha, A. B.; Apel, M. A.; Sobral, M. E. G.; Henriques, A. T.; Zuanazzi, J. A. S.; *Phytomedicine* **2008**, *15*, 882.

4. da Silva, A. F. S.; de Andrade, J. P.; Bevilaqua, L. R.; de Souza, M. M.; Izquierdo, I.; Henriques, A. T.; Zuanazzi, J. A. S.; *Pharmacol., Biochem. Behav.* **2006**, *85*, 148.

5. Pagliosa, L. B.; Monteiro, S. C.; Silva, K. B.; de Andrade, J. P.; Dutilh, J.; Bastida, J.; Cammsrota, M.; Zuanazzi, J. A. S.; *Phytomedicine* **2010**, *17*, 698.

6. Kornienko, A.; Evidente, A.; *Chem. Rev.* **2008**, *108*, 1982.

7. Efferth, T.; Saeed, M. E. M.; Kadioglu, O.; Seo, E. J.; Shirooie, S.; Mbaveng, A. T.; Nabavi, S. M.; Kuete, V.; *Biotechnol. Adv.* **2020**, *38*, 107342.

8. Dutta, S.; Mahalanobish, S.; Saha, S.; Ghosh, S.; Sil, P. C.; *Food Chem. Toxicol.* **2019**, *128*, 240.

9. Davidson, E. K.; Brimble, M. A.; *Curr. Opin. Chem. Biol.* **2019**, *52*, 1.

10. http://floradobrasil.jbrj.gov.br/jabot/floradobrasil/FB26367 accessed in June 2020.

11. Costa, G. G. P.; Silva, C. A. G.; Gomes, J. V. D.; Torres, A. G.; Santos, I. R. I.; de Almeida, F. T. C.; Luiz, C. W. F.; Simeoni, A.; Silveira, D.; Gomes-Copeland, K. K. P.; *Rev. Bras. Farmacogn.* **2019**, *29*, 262.

12. *AMDIS Automated Mass Spectral Deconvolution and Identification System*, v. 2.65; MA, USA, 2008.

13. *GraphPad Prism* v. 8.0; GraphPad Software, San Diego, USA, 2018.

14. *HyperChem 8.0.10*; Hypercube, Inc., Gainesville, USA, 2011.

15. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery Jr., J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J.; *Gaussian 09*, Revision A.02; Gaussian: Wallingford, CT, 2009.

16. *Origin* 8.0; OriginLab, Northampton, USA, 2007.

17. Wang, Y. H.; Zhang, Z. K.; Yang, F. M.; Sun, Q. Y.; He, H. P.; Di, Y. T.; Mu, S. Z.; Lu, Y.; Chang, Y.; Zheng, Q. T.; Ding, M.; Dong, J. H.; Hao, X. J.; *J. Nat. Prod.* **2007**, *70*, 1458.

18. Cimmino, A.; Masi, M.; Evidente, M.; Superchi, S.; Evidente, A.; *Chirality* **2017**, *29*, 486.

19. Pettit, G. R.; Pettit III, G. R.; Backhaus, R. A.; Boyd, M. R.; Meerow, A. W.; *J. Nat. Prod.* **1993**, *56*, 1682.

20. Berkov, S.; Bastida, J.; Viladomat, F.; Codina, C.; *Talanta* **2011**, *83*, 1455.

21. Berkov, S.; Osorio, E.; Viladomat, F.; Bastida, J. In *The Alkaloids: Chemistry and Biology*, vol. 83; Elsevier: Cambridge, 2020, p. 113.

22. Schnoes, H. K.; Smith, D. H.; Burlingame, A. L.; Jeffs, P. W.; Dopke, W.; *Tetrahedron* **1962**, *24*, 2825.

23. Jeffs, P. W.; Abou-Donia, A.; Campau, D.; Staiger, D.; *J. Org. Chem.* **1985**, 50, 1732.

24. Latvala, A.; Önür, M. A.; Gözler, T.; Linden A.; Kivçak, B.; Hesse, M.; *Phytochemistry* **1995**, *39*, 1229.

25. Ghosal, S.; Saini, K. S.; Razdan, S.; *Phytochemistry* **1985**, *24*, 2141.

26. Pigni, N. B.; Berkov, S.; Elamrani, A.; Benaissa, M.; Viladomat, F.; Codina, C.; Bastida, J.; *Molecules* **2010**, *15*, 7083.

27. Bastida, J.; Berkov, S.; Torras, L.; Pigni, N. B.; de Andrade, J. P.; Martínez, V.; Codina, C.; Viladomat, F.; *Recent Adv. Pharm. Sci.* **2011**, 65.

28. Weirich, L.; Merten, C.; *Phys. Chem. Chem. Phys.* **2019**, *21*, 13494.

29. Pagning, A. L. N.; Tamokou, J. D.; Khan, M. L.; Ali, M. I.; Hameed, A.; Ngnokam, D.; Tapondjou, L. A.; Kuiate, J. R.; Ali, M. S.; *S. Afr. J. Bot.* **2016**, *102*, 166.

30. Kobayashi, S.; Yuasa, K.; Imakura, Y.; Kihara, M.; Shingu, T.; *Chem. Pharm. Bull.* **1980**, *28*, 3433.

31. Mosmann, T.; *J. Immunol. Methods* **1983**, *65*, 55.

32. van Goietsenoven, G.; Mathieu, V.; Lefranc, F.; Kornienko, A.; Evidente, A.; Kiss, R.; *Med. Res. Rev.* **2013**, *33*, 439.

33. Pettit, G. R.; Eastham, S. A.; Melody, N.; Orr, B.; Herald, D. L.; McGregor, J.; Knight, J. C.; Doubek, D. L.; Pettit III, G. R.; Garner, L. C.; Bell, J. A.; *J. Nat. Prod.* **2006**, *69*, 7.

34. Carvalho, K. R.; Silva, A. B.; Torres, M. C. M.; Pinto, F. C. L.; Guimarães, L. A.; Rocha, D. D.; Silveira, E. R.; Costa-Lotufo, L. V.; Braz-Filho, R.; Pessoa, O. D. L.; *J. Braz. Chem. Soc.* **2015**, *26*, 1976.

35. Katoch, D.; Kumar, D.; Padwad, Y. S.; Singh, B.; Sharma, U.; *Nat. Prod. Res.* **2019**, DOI 10.1080/14786419.2019.1574785.

36. Vergura, S.; Santoro, E.; Masi, M.; Evidente, A.; Scafato, P.; Superchi, S.; Mazzeo, G.; Longhi, G.; Abbate, S.; *Fitoterapia* **2018**, *129*, 78.